相关实验视频

Updated: Jun 2, 2025

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

治疗含义和全面的洞察力细胞衰老和老化在瘤微环境的肉瘤

Pengfei Zan¹, Yi Zhang², Yidong Zhu³

¹Department of Orthopedics, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200080, China.

Discover oncology

|January 15, 2025

概括

衰老,细胞的衰老,影响肉瘤 (SARC) 的进展和预后. 研究人员使用三个基因 (RAD54,PIK3IP1,TRIP13) 开发了一种衰老预测器,以确定更好的SARC治疗策略的生物标志物.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
生物标志物发现发现

背景情况:

肉瘤 (SARC) 是一种带细胞间瘤,预后不好.
瘤微环境 (TME) 中的衰老细胞越来越多地与癌症的进展和转移有关.
在SARC中衰老的作用仍然不完全理解.

研究的目的:

为了研究衰老水平,年龄和瘤微环境 (TME) 之间的关联.
确定与衰老相关的基因,并开发SARC预后的预测模型.
为了验证开发的衰老预测器的预后和病理相关性.

主要方法:

使用了权重基因共同表达网络分析 (WGCNA) 和最小绝对收缩和选择运算符 (LASSO) 算法.
使用三个已识别的基因构建了一个衰老预测器:RAD54,PIK3IP1和TRIP13.
使用独立队列,免疫组织化学和定量逆转录聚合酶链反应 (qRT-PCR) 进行了验证.

主要成果:

发现衰老水平和患者年龄与TME,免疫治疗指标和SARC的预后有关.
一个强大的衰老预测器被开发和验证,证明了预后和病理相关性.
该预测器提供了对SARC分子机制的洞察,并确定了潜在的预后生物标志物.

结论:

开发的衰老预测器为了解SARC分子机制提供了一个新的工具.
确定了与衰老相关的基因和预测因子,有望为SARC开发有针对性的治疗策略.
这项研究强调了细胞衰老对肉瘤进展和患者结果的重要性.

关键词:

衰老的衰老衰老的衰老细胞衰老细胞衰老这种类型的肉瘤是sarcoma.瘤微环境是一个微环境.

更多相关视频

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Replicative Cell Senescence

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...